These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 37538794)
21. Identification of an epithelial-mesenchymal transition-related lncRNA prognostic signature for patients with glioblastoma. Yang X; Niu S; Liu J; Fang J; Wu Z; Ling S; Di G; Jiang X Sci Rep; 2021 Dec; 11(1):23694. PubMed ID: 34880375 [TBL] [Abstract][Full Text] [Related]
22. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma. Chen S; Zhao E Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631 [TBL] [Abstract][Full Text] [Related]
23. Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma. Zhou Y; Wang L; Zhang W; Ma J; Zhang Z; Yang M; Yu J; Luo J; Yan Z Dis Markers; 2022; 2022():6335155. PubMed ID: 35111268 [TBL] [Abstract][Full Text] [Related]
24. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer. Yang M; Sun Y; Ji H; Zhang Q Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659 [TBL] [Abstract][Full Text] [Related]
25. Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer. Zhou M; Lv S; Hou Y; Zhang R; Wang W; Yan Z; Li T; Gan W; Zeng Z; Zhang F; Yang M Front Immunol; 2022; 13():994874. PubMed ID: 36330513 [TBL] [Abstract][Full Text] [Related]
26. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
27. Development of a Ten-lncRNA Signature Prognostic Model for Breast Cancer Survival: A Study with the TCGA Database. Zhou W; Pang Y; Yao Y; Qiao H Anal Cell Pathol (Amst); 2020; 2020():6827057. PubMed ID: 32908814 [TBL] [Abstract][Full Text] [Related]
28. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma. Xu BH; Jiang JH; Luo T; Jiang ZJ; Liu XY; Li LQ Medicine (Baltimore); 2021 Jul; 100(30):e26762. PubMed ID: 34397721 [TBL] [Abstract][Full Text] [Related]
29. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients. Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y Front Immunol; 2021; 12():805883. PubMed ID: 35095892 [TBL] [Abstract][Full Text] [Related]
30. Development of a novel five-lncRNA prognostic signature for predicting overall survival in elderly patients with breast cancer. Luo Y; Zhang Y; Wu YX; Li HB; Shen D; Che YQ J Clin Lab Anal; 2022 Jan; 36(1):e24172. PubMed ID: 34894405 [TBL] [Abstract][Full Text] [Related]
31. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature. Ma W; Zhao F; Yu X; Guan S; Suo H; Tao Z; Qiu Y; Wu Y; Cao Y; Jin F J Transl Med; 2020 Nov; 18(1):442. PubMed ID: 33225954 [TBL] [Abstract][Full Text] [Related]
32. Identification and validation of biomarkers for epithelial-mesenchymal transition-related cells to estimate the prognosis and immune microenvironment in primary gastric cancer by the integrated analysis of single-cell and bulk RNA sequencing data. Shen K; Ke S; Chen B; Zhang T; Wang H; Lv J; Gao W Math Biosci Eng; 2023 Jun; 20(8):13798-13823. PubMed ID: 37679111 [TBL] [Abstract][Full Text] [Related]
33. The nomogram based on the 6-lncRNA model can promote the prognosis prediction of patients with breast invasive carcinoma. Luo D; Yao W; Wang Q; Yang Q; Liu X; Yang Y; Zhang W; Xue D; Ma B Sci Rep; 2021 Oct; 11(1):20863. PubMed ID: 34675301 [TBL] [Abstract][Full Text] [Related]
34. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients. Wang JM; Li X; Yang P; Geng WB; Wang XY BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810 [TBL] [Abstract][Full Text] [Related]
35. A pyroptosis-related lncRNA signature predicts prognosis and immune microenvironment in head and neck squamous cell carcinoma. Zhu W; Ye Z; Chen L; Liang H; Cai Q Int Immunopharmacol; 2021 Dec; 101(Pt B):108268. PubMed ID: 34688154 [TBL] [Abstract][Full Text] [Related]
36. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma. Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420 [TBL] [Abstract][Full Text] [Related]
37. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer. Li C; Zhang Y BMC Med Genomics; 2023 Jul; 16(1):158. PubMed ID: 37422644 [TBL] [Abstract][Full Text] [Related]
38. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer. Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K Front Immunol; 2022; 13():947802. PubMed ID: 36405735 [TBL] [Abstract][Full Text] [Related]
39. Comprehensive analysis of ICD-related lncRNAs in predicting risk stratification, clinical prognosis and immune response for breast cancer. Wang Y; Yue T; He Q Aging (Albany NY); 2023 Sep; 15(17):8833-8850. PubMed ID: 37695742 [TBL] [Abstract][Full Text] [Related]
40. Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma. Xia QD; Zhang Y; Li LS; Lu JL; Xun Y; Sun JX; Xu JZ; Liu CQ; Lu YC; He D; Wang SG Dis Markers; 2022; 2022():8131007. PubMed ID: 35371341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]